Background: Patients treated with chemoradiotherapy (CRT) for head and neck cancers often require feeding tubes (FTs) due to toxicity. We sought to identify factors associated with a prolonged FT requirement.
introduction Chemoradiotherapy (CRT) has become a standard treatment modality for patients with locally advanced squamous cell carcinomas of the head and neck either as definitive treatment or in the postoperative setting [1] . The addition of concurrent chemotherapy to radiation therapy has led to improvements in tumor response, local control, and organ preservation rates, but CRT increases the frequency of clinically significant acute and potentially late toxic effects to normal adjacent tissue when compared with radiation therapy alone [2] [3] [4] [5] [6] [7] [8] [9] . While advances in radiation therapy, such as intensity-modulated radiation therapy (IMRT), have been shown to reduce the rates and severity of certain toxic effects associated with CRT, notably xerostomia, others remain problematic including dysphagia [10] [11] [12] [13] [14] .
The intrinsic characteristics of a head and neck tumor, including site, volume, and extent of disease, can contribute to dysphagia. In addition, CRT-related side effects, including mucositis and xerostomia, play a role in the disruption of swallowing function. Eisbruch et al. carried out videofluoroscopic (VF) analyses in patients undergoing CRT for head and neck cancers to identify those anatomic structures whose injury would lead to dysphagia. It appeared that the dose and subsequent injury to the pharyngeal constrictor (PC) muscles, supraglottic larynx (SGL), and glottic larynx (GL) during CRT played a major role in the development of dysphagia [15] . Dysphagia is associated with malnutrition and aspiration. Aspiration, in turn, especially when combined with neutropenia caused by chemotherapy can lead to aspiration pneumonia, sepsis, and death [16] [17] [18] . In some patients, as a means of overcoming malnutrition and preventing aspiration, supplemental nutrition via a feeding tube (FT) is required. While FTs provide patients the nutritional intake they so vitally need both during and after CRT, the physical and psychological impact of having a FT, as well as the complications associated with FT placement, can significantly impair a patient's quality of life [19, 20] .
In this study, we sought to determine clinical and dosimetric factors associated with a prolonged FT requirement, defined in this study as requiring a FT for nutritional support for ‡6 months following CRT. A 6-month duration of tube feeding following CRT was selected to define prolonged tube feeding because it represents a clear marker of late toxicity.
patients and methods Table 1 . One percent, 24%, and 75% of the patients in the study had stage II, stage III, and stage IV diease respectively. Seventy-three patients (91%) had squamous cell carcinomas. Fifty-seven patients (71%) were treated with definitive CRT, while 23 (29%) were treated in the postoperative setting. Three patients who had tumors of the skull base or ear canal were included in the analysis because they had advanced disease that necessitated comprehensive irradiation of the neck. The majority of patients were treated on clinical protocols utilizing several induction and concurrent chemotherapy regimens. Of those treated with definitive CRT, 25 (44%) received induction chemotherapy followed by concurrent CRT. The various schedules of systemic therapies utilized are shown in Table 1 .
Radiation was delivered using IMRT (99%) or three-dimensional conformal radiotherapy (1%) with doses ranging from 59.4 to 74 Gy (median 70 Gy). We retrospectively contoured the PC muscles, SGL, and GL on all patient radiation treatment plans. In this study, no attempt had been made at the time of radiation treatment planning to restrict dose to the PC muscles. In some patients, attempts to limit dose to the GL were made. The mean dose received by the PC muscles, SGL, and GL, as well as the percentage volume of each structure receiving 40 Gy (V40), 50 Gy (V50), 60 Gy (V60), and 70 Gy (V70) were collected. The superior, middle, and inferior PCs were contoured as one single structure ( Figure 1 ) using guidelines as described by Eisbruch et al. [15] . In addition, clinically related factors (e.g. age, sex, stage, and site of primary) were collected and analyzed.
The start date of duration of FT dependence was set as the date of FT placement for those patients who had the FT placed during CRT and at the date of completion of CRT in those patients who had the tube placed before CRT. The end date of duration of FT dependence was the date of FT removal or the date of last follow-up with the FT in place. Patients with FTs in place with <6 months of follow-up from the start date of FT dependence or those who developed recurrent/progressive disease with the FT in place original article
Annals of Oncology within 6 months of the start date of FT dependence were censored from the analysis. The policy of FT placement at our institution was the following: prophylactic FT placement was reserved for those patients who had significant weight loss before therapy (typically ‡10% of baseline body weight), who did not have functional swallowing ability due to tumor mass, or who were high aspiration risks. Indications for placement during CRT included a drop in baseline (pretreatment) weight >5%, inability to swallow, or a high aspiration risk. Baseline swallowing studies were not carried out on all patients though those on clinical protocols were required to do so. Swallowing studies were generally not carried out during CRT unless clinically indicated. Aggressive post-CRT swallowing therapy was given to those patients with dysphagia, but not required for all patients.
Statistical analysis was carried out using SPSS version 16.0 software (SPSS, Inc., Chicago, IL). Multivariate analysis of the length of time that a FT was required was carried out using the Cox proportional hazards model with stepwise forward regression. Multivariate logistic modeling of FT requirement for ‡6 months was carried out with stepwise forward regression. All analyses were two sided and significance was set to the level of P < 0.05.
results
Of the 80 patients in our study, 33 patients (41%) required a FT either before (15 patients) or during (18 patients) the course of CRT. All FTs were placed percutaneously. Fifteen of these patients (19%) required the FT for ‡6 months, including eight whose FT was placed before CRT and seven during CRT. Fortyseven patients did not require a FT at any time. Four patients who developed recurrent/progressive disease with the FT in place within 6 months of the start of FT placement were censored from the analysis.
Clinical variables compared between the group of patients who required a FT for ‡6 months versus those who did not are displayed in Table 2 . Having T3-T4 disease was found to be a significant factor for prolonged tube feeding (P = 0.023). Ten percent of those with T0-T2 disease required a FT for ‡6 Figure 1 . Digitally reconstructed radiograph of contoured superior, middle, and inferior pharyngeal constrictor muscles as one single structure. Table 3 . Statistically significant differences on univariate analysis were noted with respect to mean PC dose (65 versus 60 Gy; P = 0.047), PC-V60 (74% versus 59%, P = 0.031), PC-V70 (41% versus 25%, P = 0.008), mean SGL dose (64 versus 57 Gy; P = 0.048), and SGL-V70 (45% versus 26%, P = 0.046). No differences were noted with respect to the other dosimetric variables.
On multivariate analysis, PC-V70 and having T3-4 disease remained the only factors associated with a prolonged FT. Using the Cox proportional hazards model, T3-T4 disease status appeared to be the stronger factor (T3-T4, P = 0.036; PC-V70, P = 0.078). Using logistic regression, PC-V70 appeared to be the stronger indicator (PC-V70, P = 0.039; T3-T4, P = 0.057). Patients with a PC-V70 <30% (n = 25) had an 8% risk of requiring a FT for ‡6 months, while patients with a PC-V70 ‡30% (n = 46) had a 28% risk of requiring a FT for ‡6 months. A plot representing the risk of requiring a FT for ‡6 months with respect to PC-V60 and PC-V70 based on logistic regression is shown in Figure 2 . A Kaplan-Meier plot of the duration of FT requirement related to PC-V70 is shown in Figure 3 .
Because of the significance of PC-V70, further analyses of factors likely associated with higher PC-V70 values were carried out. Patients with T3-T4 disease had a mean PC-V70 of 34% versus 24% for those with T0-T2 tumors (P = 0.06). Patients with advanced nodal disease (N2-N3), who were not found to have a higher rate of long-term FT dependence on univariate or multivariate analysis, did have higher PC-V70 values (34% versus 19%, P = 0.002) than those with N0-N1 disease. Lastly, when patients with laryngeal or hypopharyngeal primary tumors were isolated from all other patients, the difference in PC-V70 approached, but did not reach, statistical significance (larynx/hypopharynx-36% versus all other sites-26%, P = 0.09). Patients with laryngeal/hypopharyngeal tumors were not original article Annals of Oncology found to have a higher rate of long-term FT dependence ‡6 months after CRT compared with all other patients (81% versus 80%, respectively, P = 0.91).
discussion
Swallowing is a complex process that requires the coordination of >30 muscle pairs and multiple cranial nerves under both voluntary and involuntary control [15] . It is divided into three phases: oral, pharyngeal, and esophageal. With mastication, a food bolus is formed that is pushed by the tongue against the hard plate during the oral phase of swallowing. This is followed by the pharyngeal phase, which involves the elevation of the tongue and depression of the soft palate, which pushes the food bolus into the oropharynx. Simultaneously during the pharyngeal phase, the epiglottis and soft palate close the airway and palatopharynx preventing aspiration and regurgitation [21] . Elevation of the larynx and pharynx are critical for protecting the airway and propelling the food bolus [15] . Finally, during the esophageal phase, the bolus passes into the esophagus [21] . Inherently, the presence of a tumor mass in the head and neck can disrupt the process of swallowing and it is not surprising that dysphagia is often a presenting symptom [21] . Moreover, the treatment of head and neck cancers with CRT, which often requires large treatment volumes encompassing the gross tumor and areas at risk of harboring microscopic disease, increases the risk of compromise of swallowing function. The possibility of resulting disruption in closure of the airway during swallowing, particularly in the case of laryngeal and hypopharyngeal cancers, can lead to life-threatening aspiration. In the VF analyses of Eisbruch et al. [15] in patients undergoing CRT, it appeared that CRT could lead to weakness and incomplete posterior motion of the base of tongue, prolonged pharyngeal transit time, discoordination of the swallowing phases, accumulation of food residue in the pharynx, and lack of laryngeal elevation and closure during swallowing. Their analysis concluded that damage to the PCs, GL, and SGL likely contributed to the risk of dysphagia as a result of treatment and that IMRT could be used to potentially reduce radiation dose to these structures [15] .
In this study, we sought to correlate dosimetric factors of therapy that would predict the need of a prolonged FT requirement of ‡6 months. Reports of the need for long-term feeding need in patients treated with CRT have varied in the literature. Nguyen et al. [22] reported in a study of 55 patients treated with concurrent cisplatin/5-fluorouracil that 45% required a FT for >3 months or needed dilation because of pharyngeal stenosis. Staton et al. [23] reported that 16 of 45 patients (36%) treated with concurrent cisplatin and radiotherapy for locally advanced laryngeal cancer required a FT for ‡6 months. In a study of 30 patients treated with CRT for advanced stage III/IV oropharyngeal cancer, Shiley et al. [24] reported that 81% had a FT placed before or during therapy and that two-thirds were FT dependent at 3 months after therapy with patients having a base of tongue or tonsillar primary having a higher rate of percutaneous endoscopic gastrostomy tube dependence. At more than 1 year after CRT, 19% of patients treated with concurrent cisplatin and RT in the postoperative setting were reported by Ackerstaff et al. [25] to have a FT. Samant et al. [26] reported that 30% of patients treated with definitive concurrent cisplatin and RT for advanced piriform sinus required a FT for >1 year.
In our analysis of 80 patients treated with CRT for head and neck cancers, 41% required a FT either before or during therapy and 19% required the FT for ‡6 months. In this longterm FT need group, we found that on multivariate analysis the only factor that was predictive of a prolonged FT requirement was PC-V70. When this value exceeded 30%, the risk of a prolonged FT was 28%. This is concordant with the findings from Feng et al. [27] . They reported in their prospective study of 36 patients treated with concurrent CRT that the dose to the PCs correlated with dysphagia and aspiration. All patients in the study who developed aspiration had a PC-V65 >50% and all patients (n = 3) who developed strictures had a PC-V70 >50% [27] . Levendag et al. [28] found in their study of 81 patients treated with RT for oropharyngeal cancers that 23% experienced severe grade 3-4 dysphagia and that the dose to the superior and middle constrictor muscles correlated with the severity of dysphagia. With every additional 10 Gy above 55 Gy to the superior and middle constrictors, a 19% increase in the probability of dysphagia was found [28] .
Our analysis identified advanced T stage (T3-T4) as a clinical factor associated with a prolonged FT requirement. This is a similar finding to that of Mangar et al. [29] who attempted to identify pretreatment clinical factors that could predict patients at high risk of requiring FTs either before or during radiation treatment for head and neck cancers. They also found advanced stage as a predictive factor for FT need in their cohort of 160 patients. Other factors found to be predictive for FT need include body mass index, performance status, pretreatment weight loss, low serum albumin, age and smoking [28] . That our study did not identify other significant clinical factors may be the result of several factors including our relatively small sample size and our specific measure of dysphagia, notably having a FT ‡6 months after CRT. Other measures of dysphagia such as the presence/degree of aspiration, stricture formation, pre-CRT swallowing function, or the need of a FT for any length of time may have demonstrated clinical factors that were significant. For some, FT dependence can sometimes occur as a result of convenience or CRT-related dysgeusia. At our institution, we aggressively encourage patients to continue to swallow despite having a FT. We argue that continued swallowing must take precedence over convenience or the presence of taste changes. Therefore, we do not believe that these played a major factor in FT dependence in our cohort.
FTs can cause discomfort, psychosocial distress, and social isolation. Patients with FTs report significantly worse quality of life in the post-CRT period compared with those who do not [19, 20] . In addition, reliance on tube feeds with a subsequent reduction in oral intake has the potential to result in atrophy of the swallowing mechanism and long-term dysphagia [30] [31] [32] [33] [34] . Our study demonstrates links between both advanced T stage and PC muscle dose during CRT with an increased risk of requiring a long-term FT. While advanced T stage is a presenting factor for which no adjustment can be made, in the IMRT era, there are opportunities to potentially reduce the radiation dose to the PCs. During the contouring process, a careful assessment of sites at risk and not at risk for harboring microscopic disease can provide avenues for PC muscle sparing. The medial retropharyngeal lymph nodes located posterior to the PCs provide such an opportunity. The medial retropharyngeal nodes are rarely involved and can be excluded from clinical target volumes in the majority of cases, thereby providing a potential reduction in dose to the PC muscles [27] . Additionally, the PC muscles can be contoured as a separate structure and dose volume constraints can be attempted.
Comprehensive treatment of certain head and neck tumors, such as a base of tongue primaries, may preclude dose constraints on the PC muscles with IMRT. Alternatives, such as brachytherapy boosts, may provide satisfactory tumor coverage and limitation of dose to critical structures [35] . Reduction of dose to the PC muscles may reduce the need for a long-term FT requirement by reducing the risk of certain swallowing abnormalities seen following CRT, notably ineffective elevation of the larynx and pharynx during swallowing which is required for protecting the airway and propulsion of the food bolus [27] . However, the causes of dysphagia in patients treated with CRT are not uniform. In a prospective analysis of patients treated with CRT, Eisbruch et al. [36] reported that 35% (7 of 20) exhibited abnormal larynx/pharynx elevation in the first 1-3 months following CRT and that 46% (6 of 13) showed the same abnormality 6-12 months following CRT. The same study demonstrated that 35% and 46% of patients demonstrated upper esophageal stricture at the same time points of 1-3 and 6-12 months following CRT, respectively [36] . Therefore, while a reduction in dose to the PC muscles may reduce the risk of certain causes of a potential need for a long-term FT, it would not reduce the risk of all causes such as upper esophageal stricture.
Certainly, there are a number of limitations of this study including it being a retrospective study. There was a large degree of heterogeneity within this patient population in terms of both local (i.e. definitive CRT versus postoperative CRT, type of surgery) and systemic therapies utilized. These differences could have been confounding factors that had an impact on the severity of symptoms during and after CRT and therefore played a role in the need for long-term FT. Another limitation of this study was our end date of FT dependence. We utilized the date of FT removal or the date of last follow-up with the FT in place as proxies for the end date of FT dependence. These end points may not accurately measure when the patients actually stopped using their FTs. However, determining the actual date by which patients stopped using their FTs was not possible, and the end points used seemed to be the most reliable and appropriate.
conclusions
In a new finding, our study suggests an apparent association between PC dose and an increasing risk of a prolonged FT requirement. As a result of this study or institution now routinely contours, the PC muscles during IMRT planning to limit its dose. Attempts are made to limit the PC-V70 to £30%. Prospective studies attempting to limit the PC-V70 will need to be done to determine whether this can help reduce the risk of prolonged tube feeding in patients receiving CRT for head and neck cancers. 
